TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01194453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin, dexamethasone,vitamin B12, folic acid
Description: Patients received cisplatin 75mg/m2 plus pemetrexed 500 mg/m2 on day 1.Chemotherapy was repeated every 3 weeks for a maximum of six cycles.Patients received dexamethasone prophylaxis of 3.75mg orally twice per day on the day before, the day of, and the day after each day-1 treatment. patients received oral folic acid (1,000ug)daily and a vitamin B12 injection (1,000 ug) every 9 weeks, beginning 1 to 2 weeks before the first dose and continuing until 3 weeks after the last dose of study treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin, gemcitabine
Description: cisplatin 75mg/m2 on day 1 plus gemcitabine 1000 mg/m2 on days 1 and 8
Study: NCT03202823

Intervention type: PROCEDURE
Intervention: blood samples
Description: 3 tubes (5 ml volume) collected during surgery

Intervention type: PROCEDURE
Intervention: blood samples
Description: 3 tubes (5 ml volume) collected during surgery

Intervention type: PROCEDURE
Intervention: recover samples of atheromatous plaque
Description: a carotid sample collected during surgery

Intervention type: PROCEDURE
Intervention: recover samples of atheromatous plaque
Description: a carotid sample collected during surgery
Study: NCT04828187

Intervention type: DIAGNOSTIC_TEST
Intervention: Comparison of the proposed artificial network with the ground truth
Description: Both eyes will be included for each study participant. Participants watched a 4-10-minute video in standard mesopic environmental lighting conditions at 3.5m viewing distance. Simultaneously, all blinking moves will be recorded through a web infrared camera.~The proposed system was tested on the 8 different subjects. Several metrics of blink detection and classification accuracy were calculated against the ground truth, which was generated by 3 independent experts, whose conflicts were resolved by a senior expert. Two independent blink identifications are assumed to be in agreement, if and only if there is sufficient temporal overlapping and the type of blink is the same between the DLED system and the ground truth.
Study: NCT01837069

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol
Description: 25mg PO BID if the HR is elevated at preadmission testing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisinopril
Description: 2.5mg PO QD if the HR is elevated at preadmission testing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: 80mg PO QD at preadmission testing

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle counseling
Description: Diet, exercise, medication adherance and smoking counseling
Study: NCT02217436

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iPad
Description: iPad with age-appropriate applications, videos, and music

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: All study participants will receive standard care, which consists of procedural explanation and preparation by providers, verbal encouragement and comforting by providers and parents, and topical anesthetic (LET) followed by injectable lidocaine administration (whether one or both of these anesthetics will be used will be determined by the provider prior to randomization).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: All study participants will receive standard care, which consists of procedural explanation and preparation by providers, verbal encouragement and comforting by providers and parents, and topical anesthetic (LET) followed by injectable lidocaine administration (whether one or both of these anesthetics will be used will be determined by the provider prior to randomization).
Study: NCT03974399

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Bacopa Monnieri
Description: subjects will take Bacopa Monnieri daily for 3 months
Study: NCT04612036

Intervention type: DEVICE
Intervention: Journey II Bi-Cruciate Stabilized TKA
Description: Total Knee Arthroplasty System

Intervention type: DEVICE
Intervention: Journey II Cruciate Retaining TKA
Description: Total Knee Arthroplasty System

Intervention type: DEVICE
Intervention: Journey II Bi-Cruciate Retaining TKA
Description: Total Knee Arthroplasty System
Study: NCT02020057

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee arthroplasty
Description: Total knee arthroplasty with standard incision and approach, and cement fixation. Zimmer Nexgen posterior stabilized total knee implants are used.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty
Description: Total knee arthroplasty with standard incision and approach, and cement fixation. Zimmer Nexgen posterior stabilized total knee implants are used.
Study: NCT00437502

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tumor peptide vaccine
Description: Cohort 1 low dose level of vaccine @ 0.3 mg administered as x1 weekly injection given intradermally/subcutaneously into site assigned( same limb) for total number of study vaccine injections = 6.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tumor peptide vaccine
Description: Cohort 2 high dose vaccine @ 1 mg administered as x1 weekly injection given intradermally/subcutaneously into site assigned( same limb) for total number of study vaccine injections = 6.
Study: NCT04641299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8233
Description: PCSK9-targeted ASO for the reduction of circulating levels of LDL-C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8233
Description: PCSK9-targeted ASO for the reduction of circulating levels of LDL-C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8233
Description: PCSK9-targeted ASO for the reduction of circulating levels of LDL-C.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution
Study: NCT00311376

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin Type A (200U)
Description: botulinum toxin Type A 200 U (tx 1) followed by botulinum toxin Type A 200 U (tx 2); injections into detrusor, at \> 12 weeks interval

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin Type A (300U)
Description: botulinum toxin Type A 300 U (tx 1) followed by botulinum toxin Type A 300 U (tx 2); injections into detrusor, at \> 12 weeks interval

Intervention type: OTHER
Group type: OTHER
Intervention: Normal Saline (Placebo); botulinum toxin Type A (200U)
Description: Placebo (tx 1) followed by botulinum toxin Type A 200 U (tx 2); injections into detrusor, at \> 12 weeks interval

Intervention type: OTHER
Group type: OTHER
Intervention: Normal Saline (Placebo); botulinum toxin Type A (300U)
Description: Placebo (tx 1) followed by botulinum toxin Type A 300 U (tx 2), injections into detrusor, at \> 12 weeks interval
Study: NCT03419039

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Anthocyanins
Description: Medox tablet containing 80 mg anthocyanins.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identically appearing capsules.
Study: NCT02791282

Intervention type: OTHER
Group type: OTHER
Intervention: Index test: functional dynamic contrast enhanced (DCE)-MRI
Description: Index test: functional dynamic contrast enhanced (DCE)-MRI Reference test: Ventilation-perfusion (VQ) single-photon emission computed tomography (SPECT) Follow-up per patient: clinical assessment after 6-12 months
Study: NCT02198339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBN 4096 BS

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01805596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Study: NCT04175106

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: a non-traditional (i.e., not typically available in the supermarket) blueberry cultivar bred using natural plant breeding techniques and established as having enhanced nutritive value
Description: 150 g of a non-traditional (i.e., not typically available in the supermarket) blueberry cultivar bred using natural plant breeding techniques and established as having enhanced nutritive value.~Dietary restrictions will be observed (i.e. avoidance of food or supplements containing berry phytonutrients) for 7 days before each arm visit and throughout the study days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: a standard commercially available blueberry variety (i.e., cultivar)
Description: 150 g of a standard commercially available blueberry variety (i.e., cultivar).~Dietary restrictions will be observed (i.e. avoidance of food or supplements containing berry phytonutrients) for 7 days before each arm visit and throughout the study days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: a minimally processed blueberry-rich protein bar
Description: A minimally processed blueberry-rich protein bar matched to the phytonutrient content of the 150 g of the non-traditional blueberry.~Dietary restrictions will be observed (i.e. avoidance of food or supplements containing berry phytonutrients) for 7 days before each arm visit and throughout the study days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: a control beverage of matched-nutritive content
Description: The matched nutritive content of the blueberry-rich protein bar will be dissolved in whey protein~Dietary restrictions will be observed (i.e. avoidance of food or supplements containing berry phytonutrients) for 7 days before each arm visit and throughout the study days.
Study: NCT00613353

Intervention type: OTHER
Intervention: Behavioral
Description: Participants will be asked to wear an accelerometer
Study: NCT01817907

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pill
Description: Subjects will receive a sugar pill during the placebo arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trazodone
Description: Subjects will receive trazodone during one of their treatment arm studies
Study: NCT03380351

Intervention type: BEHAVIORAL
Intervention: SCDIC interventions
Description: The research team will characterize the intervention components and their implementation strategies.
Study: NCT02761824

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Camp Discovery
Description: Activities included physical, social, emotional, sensory and spiritual activities.
Study: NCT03580239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus will be treated at a dose of 10mg/day orally once a day. One cycle of therapy consists of 28 days. The patients also receive the best supportive care.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be treated at a dose of 10mg/day orally once a day. One cycle of therapy consists of 28 days. The patients also receive the best supportive care.
Study: NCT02608060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin Beta
Description: Dosage at Initiation: Subcutaneous injection of 30000 IU administered once a week. Dosage could be increased to 30000 IU twice a week or 60000 IU once a week after 4 weeks if a blood transfusion was required or hemoglobin level did not increase by at least 0.5 g/dL versus baseline.
Study: NCT02170675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Study: NCT03611283

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mouthwash treatment
Description: 60 seconds after meals (3 times/day) during 28 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Toothpaste treatment
Description: 3 minutes after the mouthwash (3 times/day) during 28 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mouthwash placebo
Description: 60 seconds after meals (3 times/day) during 28 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Toothpaste placebo
Description: 3 minutes after the mouthwash (3 times/day) during 28 days
Study: NCT03662672

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rib raising and lumbar release
Description: Rib raising per protocol described in arm description.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham procedure
Description: Sham procedure per protocol described in arm description
Study: NCT01971983

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-velocity, low-amplitude (HVLA)
Description: With the subject lying on his/her side, the therapist will rotate the patient's trunk, flex his/her hip and knee of the upper leg. The therapist positions his caudad forearm over the hip, while the cephalad forearm lies over the patient's shoulder. The therapist's hands will be positioned over the lumbar spine's spinous process to be manipulated.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle energy (ME)
Description: This technique involves the active movement of the patient to activate a specific musculature in order to move a bony segment of a given joint in a specific direction in relation to the adjacent bone. This technique aims to restore the restricted movement of the joint in question.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Individuals in this group received a sham intervention type, in order to simulate an intervention.
Study: NCT01565044

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: motor training
Description: Subject will perform prehension exercises on an automated table. After the initiation of the arm movement, the target to be grasped is programmed to move in order to stimulate automatic motricity.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: motor training
Description: Subject will perform prehension exercises on an automated table. After the initiation of the arm movement, the target to be grasped will remain static in order to involve intentional motricity.
Study: NCT03405805

Intervention type: BIOLOGICAL
Intervention: 13-valent pneumococcal conjugate vaccine (PCV13)
Description: Vaccination with PCV13

Intervention type: BIOLOGICAL
Intervention: 13-valent pneumococcal conjugate vaccine (PCV13)
Description: Vaccination with PCV13

Intervention type: BIOLOGICAL
Intervention: 13-valent pneumococcal conjugate vaccine (PCV13)
Description: Vaccination with PCV13
Study: NCT03245567

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PLM
Description: Participants will take the PLM on the visual estimation of LVEF. They will also take a pretest, a post-test and a delayed test at 6 months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre, post, delayed test
Description: Participants will perform a pretest, a posttest and a delayed test at 6 months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre, post, delayed test
Description: Participants will perform a pretest, a posttest and a delayed test at 6 months.
Study: NCT03224819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emerfetamab
Description: Administered by intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emerfetamab
Description: Administered by intravenous (IV) infusion.
Study: NCT01567267

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental educational intervention
Description: Educational intervention consisting of a 4-day-course in Evidence-based Medicine and Good Scientific Practice combined with the method of Problem-based Learning.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard educational intervention
Description: Educational intervention on the didactics of biology (4-day-course) not containing elements of Evidence-based Medicine, Good Scientific Practice or Problem-based learning.
Study: NCT00000258

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrous oxide 10% & placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrous oxide 10% & placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrous oxide 20% & placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrous oxide 20% & placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrous oxide 30% & placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrous oxide 30% & placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrous oxide 40% and placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrous oxide 40% and placebo
Study: NCT02952404

Intervention type: PROCEDURE
Intervention: Educational workshop
Description: The educational workshop for improved perineal support during vaginal delivery
Study: NCT03623165

Intervention type: DEVICE
Intervention: Cordella™ Heart Failure System
Description: The Cordella™ Heart Failure System electronically transfers communications and data from a set of medical devices in a heart failure patient's home to a database for storage, retrieval, and display to healthcare providers.
Study: NCT00404612

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PO BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LX211
Description: 0.2 mg/kg, twice a day (BID)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LX211
Description: 0.4 mg/kg, twice a day (BID)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LX211
Description: 0.6 mg/kg, twice a day (BID)
Study: NCT02562677

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Trigeminal Nerve Stimulation
Study: NCT03210194

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Neonatal Resuscitation Training
Description: Theoretical and practical training on basic and advanced neonatal resuscitation skills, directed to personnel from remote health centers using Standard Training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MP-ICT Neonatal Resuscitation Training
Description: Theoretical and practical training on basic and advanced neonatal resuscitation skills, directed to personnel from remote health centers using Information and Communication Technologies
Study: NCT01724099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Euiiyin-tang
Description: Korean medicinal herbal drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo drug, same odor and formula as Euiiyin-tang
Study: NCT01886053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faropenem（high dose group）
Description: dosage form: Injection dosage:2400 mg frequency: Three times a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faropenem（low-dose group)
Description: dosage form: Injection dosage:2400 mg frequency: twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ertapenem
Description: dosage form: Injection dosage:1000 mg frequency: once a day
Study: NCT02170077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093
Description: BIA 2-093 (tablets) administered at increasing daily doses of 400 mg, 800 mg and 1200 mg once-daily or twice-daily, oral route

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093
Description: BIA 2-093 (tablets) administered at increasing daily doses of 400 mg, 800 mg and 1200 mg once-daily or twice-daily, oral route

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets administered orally
Study: NCT03557034

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kardia Monitoring
Description: Kardia Mobile is an FDA approved device that allows one lead ECG recording for 30 seconds using the patient's smart phone. The device has a built-in algorithm that detects AF. KardiaPro is a secure platform that allows the physician to access the patient's recording at any time. The platform can also be programmed to send a notification to the healthcare provider if AF is detected by the software.
Study: NCT02520895

Intervention type: BIOLOGICAL
Intervention: blood samplings
Description: patients will have blood samplings at different time : D0: day of inclusion = day of the first course of chemotherapy or the 1st day of the confirmation of the diagnosis (group 8) M3: 3 months (+/- 1 month) after the start of treatment (except for group 8) M6: 6 months (+/- 1 month) after the start of treatment or after the 1st day of the confirmation of the diagnosis (group 8) M12 : 12 months after the start of treatment (group 6 and 7) M18: 18 months (+/- 1 month) after the start of treatment or after the 1st day of the confirmation of the diagnosis (group 8) R: to relapse if it occurs before 18 months or at the time of first treatment if it occurs before 18 months (group 8)
Study: NCT01338623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tansulosine
Description: capsule 0,4 mg
Study: NCT03537859

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Augmented Reality
Description: Augmented reality children books. The books will have special markers. The device's camera will read the marker and show 2d and 3D animations with the book's theme.

Intervention type: OTHER
Group type: OTHER
Intervention: Non Augmented Reality
Description: Augmented reality book without electronic device. Since no electronic device will be provided, the children will not be able to see any augmented reality features of the book, making it a conventional children's book.
Study: NCT03453073

Intervention type: BEHAVIORAL
Intervention: chocolate consumption level
Description: level of consumption of 1 oz. of chocolate, as assessed at baseline

Intervention type: BEHAVIORAL
Intervention: chocolate consumption level
Description: level of consumption of 1 oz. of chocolate, as assessed at baseline

Intervention type: BEHAVIORAL
Intervention: chocolate consumption level
Description: level of consumption of 1 oz. of chocolate, as assessed at baseline

Intervention type: BEHAVIORAL
Intervention: chocolate consumption level
Description: level of consumption of 1 oz. of chocolate, as assessed at baseline

Intervention type: BEHAVIORAL
Intervention: chocolate consumption level
Description: level of consumption of 1 oz. of chocolate, as assessed at baseline

Intervention type: BEHAVIORAL
Intervention: chocolate consumption level
Description: level of consumption of 1 oz. of chocolate, as assessed at baseline

Intervention type: BEHAVIORAL
Intervention: chocolate consumption level
Description: level of consumption of 1 oz. of chocolate, as assessed at baseline

Intervention type: OTHER
Intervention: physician diagnosis of first occurrence of serious chronic disease

Intervention type: OTHER
Intervention: physician diagnosis of first occurrence of serious chronic disease